相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
M. Vogler et al.
CELL DEATH AND DIFFERENTIATION (2009)
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Nagma Khan et al.
BIOCHEMICAL JOURNAL (2008)
Role of acetylation and extracellular location of heat shock protein 90α in tumor cell invasion
Yonghua Yang et al.
CANCER RESEARCH (2008)
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma
Valeria R. Fantin et al.
CANCER RESEARCH (2008)
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
Leigh Ellis et al.
CLINICAL CANCER RESEARCH (2008)
Caspase-8 cleaves histone deacetylase 7 and abolishes its transcription repressor function
Fiona L. Scott et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
During negative selection, Nur77 family proteins translocate to mitochondria where they associate with Bcl-2 and expose its proapoptotic BH3 domain
Jennifer Thompson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells
Qun Zhou et al.
MOLECULAR CANCER RESEARCH (2008)
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Xiang-Jiao Yang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Apoptosis of lymphoma cells is abolished due to blockade of cytochrome c release despite Nur77 mitochondrial targeting
Andrzej Rapak et al.
APOPTOSIS (2007)
Histone deacetylase inhibitors selectively suppress expression of HDAC7
Milos Dokmanovic et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells
Arthur Edwards et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Histone deacetylase 7 functions as a key regulator of genes involved in both positive and negative selection of thymocytes
Herbert G. Kasler et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia
Shannon E. Mullican et al.
NATURE MEDICINE (2007)
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
CLINICAL CANCER RESEARCH (2007)
Myosin phosphatase dephosphorylates HDAC7, controls its nucleocytoplasmic shuttling, and inhibits apoptosis in thymocytes
Maribel Parra et al.
GENES & DEVELOPMENT (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells
Warren Fiskus et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction
U. M. Moll et al.
ONCOGENE (2006)
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells
Warren Fiskus et al.
BLOOD (2006)
Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt
Y-H Han et al.
ONCOGENE (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function
CW Wright et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Immunopathogenesis and therapy of cutaneous T cell lymphoma
EJ Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Phosphorylation of histone deacetylase 7 by protein kinase D mediates T cell receptor-induced Nur77 expression and apoptosis
F Dequiedt et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
P George et al.
BLOOD (2005)
Cotreatment with histone deacetylase inhibitor LAQ824 enhances apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells
F Guo et al.
CANCER RESEARCH (2004)
Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3
BZ Lin et al.
CELL (2004)
Transcriptional activation of known and novel apoptotic pathways by Nur77 orphan steroid receptor
A Rajpal et al.
EMBO JOURNAL (2003)
HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis
F Dequiedt et al.
IMMUNITY (2003)
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
MA Shipp et al.
NATURE MEDICINE (2002)
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
RL Piekarz et al.
BLOOD (2001)
Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3
H Li et al.
SCIENCE (2000)
分享论文
